7 things everyone should know about Pulmonary Fibrosis

1. What is pulmonary fibrosis?

In technical terms, fibrosis means thickening or scarring of the tissue. In this case, the normally thin, lacy walls of the air sacs in the lungs are no longer thin and lacy, but get thick, stiff and scarred, also called becoming fibrotic. With this scarring, the architecture of the lung gets stiffer and is less efficient at delivering oxygen into the blood stream. In addition, the stiffness or fibrosis of the tissue makes it more difficult to expand the lungs and breathe. It takes more effort to breathe and this additional demand of energy leads to shortness of breath.

2. What causes pulmonary fibrosis?

There are a number of known causes of pulmonary fibrosis, but there are also unknown causes called idiopathic. Exposure to toxins like asbestos, coal dust or silica (including workers in the coal mining and sandblasting industry) can lead to pulmonary fibrosis. 

Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Nuformix plc

More articles like this

Nuformix plc

Nuformix Plc Receives Second NXP001 Milestone Payment from Oxilio

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company has achieved the second milestone according to its updated NXP001 exclusive licensing agreement with Oxilio

Nuformix plc

Nuformix hosting online Q&A session on 13 June 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30

Nuformix plc

Nuformix appoints Kreston Reeves as auditor

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves LLP as auditor to the Company. The appointment of Kreston Reeves

Nuformix plc

Nuformix delighted with NXP002 study results

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a

Nuformix plc

Nuformix updates on the NXP002 programme for treatment of IPF

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a